Results 1 to 10 of about 58,993,052 (257)
Câncer de mama [PDF]
Clinical and Biomedical Research, 2022
Em um artigo especial publicado em dezembro de 1993, sob o o título de Câncer de mama: depois de 2001, os autores fizeram uma projeção sobre o que ocorreria com a epidemiologia, o diagnóstico e o tratamento do câncer de mama no início do novo milênio ...Carlos Henrique Menke, Jorge V. Biazús, José A. Cavalheiro, Nilton L. Xavier, Eliane G. Rabin, Ana C. Bittelbrunn, Rodrigo Cericatto +6 moredoaj +1 more sourceEmployment Status Among Brazilian Women With Estrogen Receptor‐Positive Nonmetastatic Breast Cancer
Cancer MedicineBackground Employment is a critical determinant of quality of life, social reintegration, and financial stability for breast cancer survivors. International studies have shown that return‐to‐work (RTW) rates vary widely, ranging from 27% to over 80 ...Daniele Assad‐Suzuki, Luciana Castro Garcia Landeiro, Danielle Laperche‐Santos, Heloisa Resende, Fernanda Cesar Moura, Sulene Cunha Sousa Oliveira, Andrea Kazumi Shimada, Renata Arakelian, Anna Luiza Zapalowski Galvão, Bruno Santos Wance deSouza, Amanda Guimarães Castro Custódio, Monalisa Ceciliana Freitas Moreira deAndrade, Yuri Cardoso Rodrigues Beckedorff Bittencourt, Maria Cristina Figueroa Magalhães, Cristiano de Pádua Souza, Carlos Eduardo Paiva, Poliana Albuquerque Signorini, Ariane Vieira Carvalho, Daniela Jessica Pereira, Laura Cereser Albaneze, Angélica Nogueira‐Rodrigues, Daniela Dornelles Rosa, Romualdo Barroso‐Sousa +22 moredoaj +1 more sourceBody Weight Status and Its Association With Patient‐Reported Outcomes in Women With Non‐Metastatic ER‐Positive Breast Cancer Undergoing Adjuvant Endocrine Therapy
Cancer MedicinePurpose To examine associations of body mass index (BMI) with sociodemographic, clinical, treatment‐related, psychosocial, and patient‐reported outcomes among women with non‐metastatic estrogen receptor‐positive (ER+) breast cancer receiving adjuvant ...Danielle Laperche‐Santos, Amanda Guimarães Castro Custodio, Fernanda Cesar Moura, Sulene Cunha Sousa Oliveira, Andrea Kazumi Shimada, Renata Arakelian, Heloisa Resende, Anna Luiza Zapalowski Galvão, Bruno Santos Wance de Souza, Monalisa Ceciliana Freitas Moreira de Andrade, Yuri Cardoso Rodrigues Beckedorff Bittencourt, Maria Cristina Figueroa Magalhães, Luciana Castro Garcia Landeiro, Poliana Albuquerque Signorini, Daniela Jessica Pereira, Angélica Nogueira‐Rodrigues, Romualdo Barroso‐Sousa, Daniele Assad‐Suzuki +17 moredoaj +1 more sourceCancer outcomes in patients eligible for adjuvant cyclin-dependent kinase 4 and 6 inhibitors but spared adjuvant chemotherapy by Oncotype Dx: A multicenter retrospective GBECAM 0520 study
BreastBackground: In pivotal CDK4/6 inhibitor (CDK4/6i) adjuvant trials, most patients received chemotherapy (CT). However, the role of CDK4/6i in patients spared CT by a genomic signature remains unclear.Leandro Jonata de Carvalho Oliveira, Daniela Dornelles Rosa, Artur Katz, Daniele Assad-Suzuki, Daniel Argolo, Solange Moraes Sanches, Laura Testa, José Bines, Rafael Aliosha Kaliks, Debora de Melo Gagliato, Romualdo Barroso-Sousa, Tatiana Strava Corrêa, Andrea Kazumi Shimada, Carlos Henrique dos Anjos, Rudinei Linck, Thais Baccili Cury Megid, Daniel Negrini Batista, Daniel Musse Gomes, Marcelle Goldner Cesca, Débora Gaudêncio, Larissa Matos Almeida Moura, Julio Antonio Pereira de Araújo, Renata Colombo Bonadio, Zenaide Silva de Souza, Juliana Rodrigues Beal, Mario Machado Lopes, Leticia Telles Sales, Júlia Leal Franco Parisi Marlière, Max Senna Mano +28 moredoaj +1 more sourceNeoadjuvant pembrolizumab plus chemotherapy in germline BRCA-mutated early triple-negative breast cancer: a multicenter real-world cohort
npj Breast CancerNeoadjuvant pembrolizumab plus chemotherapy improves outcomes in early triple-negative breast cancer, but real-world evidence in patients with pathogenic BRCA1/2 variants remains limited.Monique Celeste Tavares, Flávia C. Balint, Romualdo Barroso-Sousa, Laura Testa, Pablo Mandó, Natália C. Nunes, Sergio Alejandro Mazzotta, Micaela Rigesti, Isadora. M. Sousa, Matheus O. Andrade, Mariana Gouveia, Fernanda Madasi, José Bines, Rafael D. P. Ferreira, Daniela D. Rosa, Candice L. Santos, Mariana R. Monteiro, Zenaide S. Souza, Daniele Assad-Suzuki, Carlos H. dos Anjos, Débora M. Gagliato, Ana Maria U. Gomes, Bruna M. Zucchetti, Anezka Ferrari, Mayana L. Brito, Maria Marcela F. Monteiro, Gilmara Resende, Noele J. B. Gomes, Maria Victoria Costanzo, Solange Moraes Sanches, Vladmir C. Lima, Jose Claudio Casali Rocha, Elizabeth Santana dos Santos, Fabiana B. Makdissi, Paulo M. Hoff, Maria del Pilar Estevez-Diz, Renata Colombo Bonadio +36 moredoaj +1 more sourceNeoadjuvant pembrolizumab plus chemotherapy in older patients with early-stage triple-negative breast cancer: real-world insights from neo-real/GBECAM-0123
npj Breast CancerThe KEYNOTE-522 regimen is the standard of care for stage II–III triple-negative breast cancer (TNBC). However, older patients were underrepresented in the pivotal trial.Mariana Carvalho Gouveia, Romualdo Barroso-Sousa, Laura Lapuchesky, Laura Testa, Monique Celeste Tavares, Flávia Cavalcanti Balint, Carlos Henrique dos Anjos, Débora de Melo Gagliato, Mayana Lopes de Brito, Giuliana Colucci, Daniele Assad-Suzuki, Daniela Dornelles Rosa, Noele de Jesus Barros Gomes, Natalia Cristina Cardoso Nunes, Isadora Martins de Sousa, Matheus de Oliveira Andrade, Fernanda Madasi, Jose Bines, Mariana Savignano, Rafael Dal Ponte Ferreira, Candice Lima Santos, Maira Tavares, Mariana Ribeiro Monteiro, Zenaide Silva de Souza, Ana Maria Ulbricht Gomes, Bruna M. Zucchetti, Anezka Ferrari, Maria Marcela Fernandes Monteiro, Poliana Albuquerque Signorini, Solange Sanches, Paulo M. Hoff, Claudio Paletta, Maria del Pilar Estevez-Diz, Renata Colombo Bonadio +33 moredoaj +1 more sourceImmune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: real-world data from the Neo-Real/GBECAM 0123 study
BreastBackground: Pembrolizumab combined with neoadjuvant chemotherapy is the standard of care for stage II-III triple-negative breast cancer (TNBC) based on the KEYNOTE-522 trial.Matheus de Oliveira Andrade, Isabella Gonçalves Gutierres, Monique Celeste Tavares, Isadora Martins de Sousa, Flávia Cavalcanti Balint, Ana Carolina Marin Comini, Mariana Carvalho Gouveia, José Bines, Fernanda Madasi, Rafael Dal Ponte Ferreira, Daniela Dornelles Rosa, Candice Lima Santos, Daniele Assad-Suzuki, Zenaide Silva de Souza, Júlio Antônio Pereira de Araújo, Débora de Melo Gagliato, Carlos Henrique dos Anjos, Bruna M. Zucchetti, Anezka Ferrari, Mayana Lopes de Brito, Renata Cangussu, Maria Marcela Fernandes Monteiro, Paulo M. Hoff, Maria Del Pilar Estevez-Diz, Laura Testa, Romualdo Barroso-Sousa, Renata Colombo Bonadio +26 moredoaj +1 more source
